Suppr超能文献

对于接受近距离放射治疗前有中度下尿路症状(LUTS)的男性,改良经尿道前列腺切除术(TURP)是安全可行的。

Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible.

作者信息

Brousil Philip, Hussain Muddassar, Lynch Mark, Laing Robert W, Langley Stephen E M

机构信息

St. Luke's Cancer Centre, The Royal Surrey County Hospital NHS Foundation Trust, Guildford, Surrey, UK.

出版信息

BJU Int. 2015 Apr;115(4):580-6. doi: 10.1111/bju.12798. Epub 2014 Dec 15.

Abstract

OBJECTIVE

To report the urinary toxicity outcomes for patients at greater risk of voiding symptoms and retention who received a modified limited transurethral resection of the prostate (TURP) before low-dose rate (LDR) brachytherapy.

PATIENTS AND METHOD

Data were analysed from patients receiving the above procedures between 2006 to present, taken from the prospective brachytherapy database of 2000 patients at the St. Luke's Cancer Centre. The limited TURP (TURP(BXT) ) was performed at a median (range) of 64 (25-205) days before seed implantation with a median resection weight of 1.15 g. Selection criteria were based on patients with moderate lower urinary tract symptoms, poor flow or post-void residual urine volume (PVR), or a prominent middle lobe or high bladder neck on transrectal ultrasonography. Baseline prostate cancer characteristics, uroflowmetry, International Prostate Symptom Score (IPSS) and quality-of-life QoL scores were collected and compared with follow-up IPSS and QoL scores.

RESULTS

Data for 112 patients was gathered from the database. The TURP(BXT) resulted in statistically significant improvements before LDR brachytherapy in maximum urinary flow rate (Qmax ) and PVR, IPSS and QoL scores (the mean Qmax before vs after the TURP(BXT) was 11.3 vs 16.7 mL/s). The IPSS and QoL scores at 6 months after seed implantation were increased compared with baseline values before the TURP(BXT) (mean IPSS at 6 months 11.7 vs 9.2 before TURP(BXT) ), but no difference at 1 year (mean IPSS 9), and improved scores at 2, 3, 4 and 5 years follow-up (mean IPSS of 7.9, 5.6, 5.3 and 7.4, respectively).

CONCLUSION

The present study suggests patients at increased risk of deteriorating voiding symptoms, including urinary retention, are no longer contraindicated against LDR brachytherapy if they receive a modified TURP before seed implantation. This procedure does not appear to carry the risk of urinary incontinence thought to be associated with a conventional TURP before LDR brachytherapy.

摘要

目的

报告在接受低剂量率(LDR)近距离放射治疗前接受改良有限经尿道前列腺切除术(TURP)的、存在排尿症状和尿潴留风险较高的患者的泌尿系统毒性结局。

患者与方法

分析了2006年至今接受上述手术的患者的数据,这些数据来自圣卢克癌症中心2000例患者的前瞻性近距离放射治疗数据库。有限TURP(TURP(BXT))在种子植入前的中位(范围)时间为64(25 - 205)天进行,中位切除重量为1.15克。选择标准基于患有中度下尿路症状、尿流不畅或排尿后残余尿量(PVR)、或经直肠超声检查显示中叶突出或膀胱颈抬高的患者。收集基线前列腺癌特征、尿流率、国际前列腺症状评分(IPSS)和生活质量(QoL)评分,并与随访的IPSS和QoL评分进行比较。

结果

从数据库中收集了112例患者的数据。TURP(BXT)导致在LDR近距离放射治疗前最大尿流率(Qmax)、PVR、IPSS和QoL评分有统计学意义的改善(TURP(BXT)前后的平均Qmax分别为11.3和16.7毫升/秒)。种子植入后6个月的IPSS和QoL评分与TURP(BXT)前的基线值相比有所增加(TURP(BXT)前6个月的平均IPSS为9.2,6个月时为11.7),但1年时无差异(平均IPSS为9),在2、3、4和5年随访时评分改善(平均IPSS分别为7.9、5.6、5.3和7.4)。

结论

本研究表明,存在排尿症状恶化风险增加(包括尿潴留)的患者,如果在种子植入前接受改良TURP,则不再是LDR近距离放射治疗的禁忌证。该手术似乎不存在被认为与LDR近距离放射治疗前传统TURP相关的尿失禁风险。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验